Chargement en cours...
Temozolomide in malignant glioma
Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive malignant glioma and the most frequent primary tumor of the central nervous system. The median survival of newly diagnosed GBM patients was between 9 to 12 months prior to treatment with temozolomide being introduced. Primary resectio...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2939767/ https://ncbi.nlm.nih.gov/pubmed/20856849 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|